- In February 2022, Medtronic received approval from the U.S. Food and Drug Administration (FDA) for its Freezor and Freezor Xtra Cardiac Cryoablation Focal Catheters. These catheters are the first and only FDA-approved devices for the treatment of pediatric Atrioventricular Nodal Reentrant Tachycardia (AVNRT). This approval highlighting Medtronic's commitment to addressing complex arrhythmias in younger patients. The introduction of these specialized ablation catheters not only expands the range of treatment options for pediatric patients but also strengthens Medtronic's position within the global interventional cardiology and peripheral vascular devices market
- In June 2024, Philips introduced its Duo Venous Stent System in the U.S., designed to address venous obstructions. Having received approval in December, this innovative device aims to tackle the root causes of chronic deep venous disease, offering two distinct models tailored to various venous conditions. This advancement underscores Philips' dedication to enhancing treatment options for patients with chronic venous disease, positioning the company to strengthen its presence in the global interventional cardiology and peripheral vascular devices market
- In April 2024, the U.S. Food and Drug Administration (FDA) granted approval to Abbott for its groundbreaking Esprit BTK System, featuring an Enviroximes Eluting Resorbable Scaffold. This advanced technology is designed to manage chronic limb-threatening ischemia (CLTI) in the area beneath the knee (BTK). This approval highlights Abbott's role in advancing interventional cardiology. The Esprit BTK System is expected to enhance clinical outcomes for patients with CLTI, further strengthening Abbott's position within the global interventional cardiology and peripheral vascular devices market
- In January 2024, Cook Group launched its Slip-Cath Beacon Tip Hydrophilic Selective Catheter in the U.S. and Canada. This versatile catheter is designed for use in both vascular and nonvascular procedures, providing healthcare providers with a flexible solution across various medical applications. The introduction of this catheter highlights Cook Group’s commitment to advancing medical technology, offering a reliable tool for a wide range of interventional procedures
- In June 2023, Cook Medical expanded its Advance Serenity hydrophilic PTA balloon catheter product line by introducing new size options and expanding its availability to additional locations. Primarily used for above- and below-the-knee procedures to treat patients with Peripheral Artery Disease (PAD), the device is currently available in the U.S. and Canada, with plans for imminent availability in Europe. This expansion underscores Cook Medical's commitment to addressing the growing global demand for advanced, minimally invasive solutions for PAD treatment
